Bell Lab

Bell Lab

John Bell profile picture

Contact Information

John Bell, PhD, FRSC, FCAHS
613 737-7700 70333

501 Smyth Road, Box 926
Ottawa, ON K1H 8L6

ORCID logo

What We Do

Our research program is directed towards the identification and characterization of novel cancer killing therapeutic viruses that selectively infect and kill cancer cells, while leaving healthy cells and tissues unharmed. Not only do we discover and design new therapeutic viruses, but we also manufacture them for eventual clinical translation and commercialization.

Selected Publications

Kwame Twumasi-Boateng, Jessica L. Pettigrew, Y. Y. Eunice Kwok, John C. Bell & Brad H. Nelson. Oncolytic viruses as engineering platforms for combination immunotherapy. Nature Reviews Cancer. Published online: 25 April 2018. doi:10.1038/s41568-018-0009-4. Free full text.

Bourgeois-Daigneault MC, Roy DG, Aitken AS, El Sayes N, Martin NT, Varette O, Falls T, St-Germain LE, Pelin A, Lichty BD, Stojdl DF, Ungerechts G, Diallo JS and Bell JC. Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. Sci Transl Med. 2018 Jan 3;10(422). Free full text.

Rozanne Arulanandam, Cory Batenchuk, Fernando A. Angarita, Kathryn Ottolino-Perry, Sophie Cousineau, Amelia Mottashed, Emma Burgess, Theresa J. Falls, Naomi De Silva, Jovian Tsang, Grant A. Howe, Marie-Claude Bourgeois-Daigneault, David P. Conrad, Manijeh Daneshmand, Caroline J. Breitbach, David H. Kirn, Leda Raptis, Subash Sad, Harold Atkins, Michael S. Huh, Jean-Simon Diallo, Brian Lichty, Carolina S. Ilkow, Fabrice Le Boeuf, Christina L. Addison, J. Andrea Mc Cart and John C. Bell. VEGF-mediated induction of PRD1-BF1/Blimp1 expression sensitizes tumour vasculature to oncolytic virus infection. Cancer Cell. 2015 Aug 10;28(2):210-24. 

Carolina S. Ilkow, Monique Marguerie, Cory Batenchuk, Justin Mayer, Daniela Ben Neriah, Sophie Cousineau, Theresa Falls, Victoria Jennings, Meaghan Boileau, David Bellamy1, Donald Bastin1, Christiano Tanese de Souza1, Almohanad Alkayyal1, Jiging Zhang, Fabrice LeBoeuf1, Rozanne Arulanandam, Lawton Stubbert, Padma Sampath, Steve Thorne4, Piriya Paramanthan5, Avijit Chatterjee5, Robert M. Strieter, Marie Burdick, Christina Addison David F. Stojdl, Harold L. Atkins, Rebecca Auer, , Jean-Simon Diallo, Brian Lichty, and John C. Bell. Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. Nat Med. 2015 May;21(5):530-6.

Brian D. Lichty, Caroline J. Breitbach, David F. Stojdl, & John C. Bell. Going viral with cancer immunotherapy. Nature Reviews Cancer. 2014 03 July.

Fabrice Le Bœuf*, Cory Batenchuk*, Markus Vähä-Koskela, Sophie Breton, Dominic Roy, Chantal Lemay, Julie Cox, Hesham Abdelbary, Theresa Falls, Girija Waghray, Harold Atkins, David Stojdl, Jean-Simon Diallo, Mads Kaern, John Bell. Model-based Rational Design of an Oncolytic Virus with Improved Therapeutics Potential. Nature Communications 2013 Jun 14;4:1974.

Heo, J.,Reid, T., Ruo, L., Breitbach, C.,Rose, S., Bloomston, M., Cho, M., Lim, H.Y., Chung, H.C., Kim, C.W., Burke, J.,Lencioni, R., Hickman, T., Moon, A., Lee, Y.S., Kim, M.K., Daneshmand, M., Dubois, K., Longpre, L., Ngo, M., Rooney, C., Bell, J.C.,Rhee,B-G., Patt, R., Hwang, T-H., Kirn, D.H., (2013) Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX 594 in liver cancer. Nat Med. 2013 Mar;19(3):329-36.

Meet the Bell Lab